BCAM
Basal cell adhesion molecule
Protein Summary
Laminin alpha-5 receptor. May mediate intracellular signaling. This gene encodes Lutheran blood group glycoprotein, a member of the immunoglobulin superfamily and a receptor for the extracellular matrix protein, laminin. The protein contains five extracellular immunoglobulin domains, a single transmembrane domain, and a short C-terminal cytoplasmic tail. This protein may play a role in epithelial cell cancer and in vaso-occlusion of red blood cells in sickle cell disease. Polymorphisms in this gene define some of the antigens in the Lutheran system and also the Auberger system. Inactivating variants of this gene result in the recessive Lutheran null phenotype, Lu(a-b-), of the Lutheran blood group. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2012]
- ENST00000270233
- ENSP00000270233
- ENSG00000187244
- LU
- MSK19
- AU
- LU
- CD239
- MSK19
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
histone modification site profile | 0.82 | ||
transcription factor perturbation | 0.74 | ||
protein domain | 0.73 | ||
tissue sample | 0.72 | ||
gene perturbation | 0.7 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 131.39 (req: < 5)
Gene RIFs: 35 (req: <= 3)
Antibodies: 354 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 131.39 (req: >= 5)
Gene RIFs: 35 (req: > 3)
Antibodies: 354 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 7
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0